InsiderDirector
RA CAPITAL MANAGEMENT, L.P. Insider Trading Activity
Every SEC Form 4 transaction reported by RA CAPITAL MANAGEMENT, L.P., sourced directly from SEC EDGAR and updated as new filings are accepted.
By Trabud · Insider-trading data from SEC EDGAR
Latest filing:
Compiled automatically from SEC EDGAR Form 4 filings and refreshed daily. Figures count purchases (code P) and sales (code S) only — not grants, option exercises, or gifts. How this page is built. Not investment advice.
Quick Answer
Is RA CAPITAL MANAGEMENT, L.P. buying or selling?
RA CAPITAL MANAGEMENT, L.P. reported 135 open-market buys ($2.9B) and 33 sells ($334.5M) across 168 Form 4 filings at 55 companies — a net buying position of $2.6B.
Source: SEC EDGAR Form 4
What stands out
- RA CAPITAL MANAGEMENT, L.P. has reported Form 4 transactions at 55 companies; the most active, Artiva Biotherapeutics, Inc. (ARTV), accounts for 11 of 168 filings (7%).
- The most recent Form 4 was accepted on Sep 21, 2026 (27 days ago).
- In the last 12 months: 25 open-market purchases ($721.5M) and 19 sales ($235.5M).
- The largest open-market purchase in the last 12 months was $423.8M of Parabilis Medicines, Inc. (PBLS) on Jun 15, 2026. SEC ↗
Key Statistics (as of Sep 21, 2026)
Total Form 4 filings
168
SEC EDGAR
Companies
55
Buys (135)
$2.9B
Sells (33)
$334.5M
Insider sentiment
Net buyingNet insider flow of $2.6B in net buying, filed between Feb 16, 2018 – Sep 21, 2026.
Companies RA CAPITAL MANAGEMENT, L.P. files for
| # | Company | Form 4 filings |
|---|---|---|
| 1 | ARTVArtiva Biotherapeutics, Inc. | 11 |
| 2 | VORVor Biopharma Inc. | 11 |
| 3 | ETNB89bio, Inc. | 10 |
| 4 | CTKBCytek Biosciences, Inc. | 8 |
| 5 | HOWLWerewolf Therapeutics, Inc. | 8 |
| 6 | ANTXAN2 Therapeutics, Inc. | 7 |
| 7 | FULCFulcrum Therapeutics, Inc. | 6 |
| 8 | WVEWave Life Sciences Ltd. | 6 |
| 9 | COAGHemab Therapeutics Holdings, Inc. | 5 |
| 10 | ELVNIMARA Inc. | 5 |
Recent RA CAPITAL MANAGEMENT, L.P. transactions
| Date | Ticker | Role | Type | Shares | Value | Filing |
|---|---|---|---|---|---|---|
| Sep 21, 2026 | SION | Director, 10% Owner | Sale | 3.4M | $21.8M | SEC ↗ |
| Aug 14, 2026 | SEPN | Director, 10% Owner | Sale | 1.5M | $63.5M | SEC ↗ |
| Jul 31, 2026 | ARTV | Director, 10% Owner | Purchase | 45.8K | $455.7K | SEC ↗ |
| Jul 28, 2026 | ARTV | Director, 10% Owner | Purchase | 41.3K | $412.8K | SEC ↗ |
| Jul 24, 2026 | ARTV | Director, 10% Owner | Purchase | 264.6K | $2.6M | SEC ↗ |
| Jul 24, 2026 | ARTV | Director, 10% Owner | Purchase | 6.5K | $58.3K | SEC ↗ |
| Jul 21, 2026 | VOR | 10% Owner | Sale | 213 | $4.2K | SEC ↗ |
| Jul 20, 2026 | ARTV | Director, 10% Owner | Purchase | 160.4K | $1.4M | SEC ↗ |
| Jul 14, 2026 | ARTV | Director, 10% Owner | Purchase | 21.7K | $194.0K | SEC ↗ |
| Jun 29, 2026 | ARTV | Director, 10% Owner | Purchase | 32.9K | $292.1K | SEC ↗ |
| Jun 22, 2026 | HOWL | 10% Owner | Sale | 416.9K | $145.9K | SEC ↗ |
| Jun 17, 2026 | COAG | 10% Owner | Purchase | 67.7K | $1.7M | SEC ↗ |
| Jun 16, 2026 | ARTV | Director, 10% Owner | Purchase | 531.3K | $4.6M | SEC ↗ |
| Jun 16, 2026 | HOWL | 10% Owner | Sale | 448.8K | $173.8K | SEC ↗ |
| Jun 15, 2026 | PBLS | Director, 10% Owner | Purchase | 21.2M | $423.8M | SEC ↗ |
| Jun 12, 2026 | HOWL | 10% Owner | Sale | 678.2K | $253.6K | SEC ↗ |
| Jun 11, 2026 | ARTV | Director, 10% Owner | Purchase | 1.0M | $7.7M | SEC ↗ |
| May 21, 2026 | COAG | 10% Owner | Purchase | 4.8K | $119.8K | SEC ↗ |
| May 14, 2026 | COAG | 10% Owner | Purchase | 6.4K | $159.0K | SEC ↗ |
| May 13, 2026 | ARTV | Director, 10% Owner | Purchase | 6.5M | $75.0M | SEC ↗ |
| May 12, 2026 | HOWL | 10% Owner | Sale | 565.2K | $390.7K | SEC ↗ |
| May 11, 2026 | COAG | 10% Owner | Purchase | 51.3K | $1.3M | SEC ↗ |
| May 6, 2026 | COAG | Director, 10% Owner | Purchase | 2.8M | $52.2M | SEC ↗ |
| Apr 24, 2026 | VOR | Director, 10% Owner | Sale | 165.2K | $2.6M | SEC ↗ |
| Apr 21, 2026 | VOR | Director, 10% Owner | Sale | 630.4K | $10.2M | SEC ↗ |
Showing the 25 most recent filings of 168. Screen every filing.
RA CAPITAL MANAGEMENT, L.P. insider trading FAQ
Is RA CAPITAL MANAGEMENT, L.P. buying or selling?
Across 168 SEC Form 4 filings, RA CAPITAL MANAGEMENT, L.P. reported 135 open-market purchases totaling $2.9B and 33 sales totaling $334.5M — a net buying position of $2.6B.
Which companies does RA CAPITAL MANAGEMENT, L.P. file Form 4s for?
RA CAPITAL MANAGEMENT, L.P. has reported insider transactions at 55 companies, most often Artiva Biotherapeutics, Inc. (ARTV), Vor Biopharma Inc. (VOR), 89bio, Inc. (ETNB), Cytek Biosciences, Inc. (CTKB), Werewolf Therapeutics, Inc. (HOWL).
How far back does RA CAPITAL MANAGEMENT, L.P.'s filing history go?
Trabud holds RA CAPITAL MANAGEMENT, L.P.'s SEC Form 4 filings from Feb 16, 2018 – Sep 21, 2026, sourced directly from SEC EDGAR.
Where does Trabud get RA CAPITAL MANAGEMENT, L.P.'s insider trading data?
Directly from SEC EDGAR Form 4 filings. Every transaction on this page is a real filing accepted by the SEC, updated as new filings arrive.
Related Content
Track RA CAPITAL MANAGEMENT, L.P. and every other insider
Screen all SEC Form 4 filings by insider, company, transaction value, and role — or ask Trabud's AI agent in plain English.
Open the screener